Study of MAG-CPT: A New Cancer Treatment
Author Information
Author(s): Bissett D, Cassidy J, de Bono J S, Muirhead F, Main M, Robson L, Fraier D, Magnè M L, Pellizzoni C, Porro M G, Spinelli R, Speed W, Twelves C
Primary Institution: University of Aberdeen, Aberdeen Royal Infirmary
Hypothesis
Can MAG-CPT improve the delivery and efficacy of camptothecin in treating solid tumors?
Conclusion
MAG-CPT can be administered safely at a dose of 200 mg/m², but no significant antitumor activity was observed.
Supporting Evidence
- 23 patients were registered in the study.
- The maximum tolerated dose was determined to be 240 mg/m².
- No objective antitumor responses were observed.
- Toxicities included myelosuppression and diarrhea.
- Patients received a median of 2 treatment cycles.
Takeaway
This study tested a new cancer drug called MAG-CPT to see if it could help deliver medicine better to tumors, but it didn't show it could shrink tumors.
Methodology
An open-label nonrandomised dose escalation study was conducted with patients having advanced solid malignancies.
Limitations
The study did not demonstrate significant antitumor activity and had a limited sample size.
Participant Demographics
{"total_patients":23,"male":15,"female":8,"age_median":62,"age_range":"33-75"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website